Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

Each ?lm-coated tablet contains 30 mg nimodipine, ? 30

PHARMACOLOGIC PROPERTIES

ATC code: C08CA06, Selective calcium channel blockers with mainly vascular e?ect, dihydropyridine derivatives Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular e?ect.
Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an e?ect which is proportionately greater in smaller than in larger vessels.
Vasoconstrictions provoked in vitro by various vasoactive substances (e.g., serotonin, prostaglandins and histamine) or by blood and blood degradation products can be prevented or reduced by up to 75 % by nimodipine.
Nimodipine binds speci?cally to L-type voltage-gated calcium channels. Nimodipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.

THERAPEUTIC INDICATIONS

Nimodipine is indicated for:
• Prevention of ischaemic neurological de?cits following aneurysmal subarachnoid haemorrhage.
• Treatment of functional disorders of the brain in elderly patients with severe symptoms. 

LEAFLETS